SEARCH

SEARCH BY CITATION

References

  • 1
    Bertoni B, Budowle B, Sans M, Barton SA, Chakraborty R. Admixture in Hispanics: distribution of ancestral population contributions in the Continental United States. Hum Biol 2003; 75: 111.
  • 2
    National Cancer Institute DCCPS Surveillance Research Program Cancer Statistics Branch. Surveillance, epidemiology, and end results (SEER) program, SEER*Stat Databases: incidence—SEER 13 Registries, public use data set, November 2004, submission vol. 2006. Available at www.seer.cancer.gov.
  • 3
    Li CI, Malone KE, Daling JR. Differences in breast cancer hormone receptor status and histology by race and ethnicity among women 50 years of age and older. Cancer Epidemiol Biomarkers Prev 2002; 11: 6017.
  • 4
    Chu KC, Anderson WF, Fritz A, Ries LA, Brawley OW. Frequency distributions of breast cancer characteristics classified by estrogen receptor and progesterone receptor status for eight racial/ethnic groups. Cancer 2001; 92: 3745.
  • 5
    Bernstein L. The risk of breast, endometrial and ovarian cancer in users of hormonal preparations. Basic Clin Pharmacol Toxicol 2006; 98: 28896.
  • 6
    ESHRE Capri Workshop Group. Hormones and breast cancer. Hum Reprod Update 2004; 10: 28193.
  • 7
    Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet 1996; 347: 171327.
  • 8
    Althuis MD, Fergenbaum JH, Garcia-Closas M, Brinton LA, Madigan MP, Sherman ME. Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiol Biomarkers Prev 2004; 13: 155868.
  • 9
    Marchbanks PA, McDonald JA, Wilson HG, Folger SG, Mandel MG, Daling JR, Bernstein L, Malone KE, Ursin G, Strom BL, Norman SA, Wingo PA, et al. Oral contraceptives and the risk of breast cancer. N Engl J Med 2002; 346: 202532.
  • 10
    Rogers A, Murtaugh MA, Edwards S, Slattery ML. Contacting controls: are we working harder for similar response rates, and does it make a difference? Am J Epidemiol 2004; 160: 8590.
  • 11
    Slattery ML, Sweeney C, Edwards S, Herrick J, Baumgartner K, Wolff R, Murtaugh M, Baumgartner R, Giuliano A, Byers T. Body size, weight change, fat distribution and breast cancer risk in Hispanic and non-Hispanic white women. Breast Cancer Res Treat 2007; 102: 85101; DOI 10.1007/s10549-006-9292-y.
  • 12
    Howard CA, Samet JM, Buechley RW, Schrag SD, Key CR. Survey research in New Mexico Hispanics: some methodological issues. Am J Epidemiol 1983; 117: 2734.
  • 13
    Word DL, Perkins RC. Building a Spanish surname list for the 1990's—a new approach to an old problem. U.S. Bureau of the Census, Population Division Working Paper No. 13. Available at http://www.census.gov/population/documentation/twpno13.pdf, 1996.
  • 14
    Edwards S, Slattery ML, Mori M, Berry TD, Caan BJ, Palmer P, Potter JD. Objective system for interviewer performance evaluation for use in epidemiologic studies. Am J Epidemiol 1994; 140: 10208.
  • 15
    Drugs@FDA; FDA approved drug products, vol. 2007. Washington, DC: U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Available at http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails.
  • 16
    Sweeney C, Edwards S, Baumgartner KB, Herrick JS, Palmer L, Murtaugh MA, Stroup A, Slattery ML. Recruiting Hispanic women for a population-based study: validity of surname search, and characteristics of non-participants. Am J Epidemiol ( 2007) (in press).
  • 17
    Division of Cancer Control and Population Sciences. The SEER program code manual, 3rd ed. Bethesda, MD: National Cancer Institute, U.S. Department of Health and Human Services, 1998.
  • 18
    Sweeney C, Wolff RK, Byers T, Baumgartner KB, Giuliano AR, Herrick JS, Murtaugh MA, Samowitz WS, Slattery ML. Genetic admixture among Hispanics and candidate gene polymorphisms: potential for confounding in a breast cancer study? Cancer Epidemiol Biomarkers Prev 2007; 16: 14250.
  • 19
    Gilliland FD, Hunt WC, Baumgartner KB, Crumley D, Nicholson CS, Fetherolf J, Samet JM. Reproductive risk factors for breast cancer in Hispanic and non-Hispanic white women: the New Mexico Women's Health Study. Am J Epidemiol 1998; 148: 68392.
  • 20
    Wenten M, Gilliland FD, Baumgartner K, Samet JM. Associations of weight, weight change, and body mass with breast cancer risk in Hispanic and non-Hispanic white women. Ann Epidemiol 2002; 12: 435444.
  • 21
    Boonstra H, Duran V, Northington Gamble V, Blumenthal P, Dominguez L, Pies C. The “boom and bust phenomenon”: the hopes, dreams, and broken promises of the contraceptive revolution. Contraception 2000; 61: 925.
  • 22
    Malone KE, Daling JR, Weiss NS. Oral contraceptives in relation to breast cancer. Epidemiol Rev 1993; 15: 8097.
  • 23
    Kahlenborn C, Modugno F, Potter DM, Severs WB. Oral contraceptive use as a risk factor for premenopausal breast cancer: a meta-analysis. Mayo Clin Proc 2006; 81: 1290302.
  • 24
    Gerstman BB, Gross TP, Kennedy DL, Bennett RC, Tomita DK, Stadel BV. Trends in the content and use of oral contraceptives in the United States, 1964–88. Am J Public Health 1991; 81: 906.
  • 25
    Gallo MF, Nanda K, Grimes DA, Schulz KF. 20 mcg versus >20 mcg estrogen combined oral contraceptives for contraception. Cochrane Database Syst Rev (Online) 2005:CD003989.
  • 26
    Althuis MD, Brogan DR, Coates RJ, Daling JR, Gammon MD, Malone KE, Schoenberg JB, Brinton LA. Hormonal content and potency of oral contraceptives and breast cancer risk among young women. Br J Cancer 2003; 88: 507.
  • 27
    Newcomer LM, Newcomb PA, Trentham-Dietz A, Longnecker MP, Greenberg ER. Oral contraceptive use and risk of breast cancer by histologic type. Int J Cancer 2003; 106: 9614.
  • 28
    Li CI, Malone KE, Porter PL, Weiss NS, Tang MT, Daling JR. Reproductive and anthropometric factors in relation to the risk of lobular and ductal breast carcinoma among women 65–79 years of age. Int J Cancer 2003; 107: 64751.
  • 29
    Strom BL, Berlin JA, Weber AL, Norman SA, Bernstein L, Burkman RT, Daling JR, Deapen D, Folger SG, Malone KE, Marchbanks PA, Simon MS, et al. Absence of an effect of injectable and implantable progestin-only contraceptives on subsequent risk of breast cancer. Contraception 2004; 69: 35360.
  • 30
    Shapiro S, Rosenberg L, Hoffman M, Truter H, Cooper D, Rao S, Dent D, Gudgeon A, van Zyl J, Katzenellenbogen J, Baillie R. Risk of breast cancer in relation to the use of injectable progestogen contraceptives and combined estrogen/progestogen contraceptives. Am J Epidemiol 2000; 151: 396403.
  • 31
    Skegg DC, Noonan EA, Paul C, Spears GF, Meirik O, Thomas DB. Depot medroxyprogesterone acetate and breast cancer. A pooled analysis of the World Health Organization and New Zealand studies. JAMA 1995; 273: 799804.
  • 32
    Breast cancer and depot-medroxyprogesterone acetate: a multinational study. WHO collaborative study of neoplasia and steroid contraceptives. Lancet 1991; 338: 8338.
  • 33
    Paul C, Skegg DC, Spears GF. Depot medroxyprogesterone (Depo-Provera) and risk of breast cancer. Br Med J 1989; 299: 75962.
  • 34
    Post-marketing surveillance of Norplant contraceptive implants. I. Contraceptive efficacy and reproductive health. Contraception 2001; 63: 16786.
  • 35
    Anderson TJ, Battersby S, King RJ, McPherson K, Going JJ. Oral contraceptive use influences resting breast proliferation. Hum Pathol 1989; 20: 113944.
  • 36
    Graham JD, Clarke CL. Physiological action of progesterone in target tissues. Endocr Rev 1997; 18: 50219.
  • 37
    Lange CA, Richer JK, Horwitz KB. Hypothesis: progesterone primes breast cancer cells for cross-talk with proliferative or antiproliferative signals. Mol Endocrinol 1999; 13: 82936.
  • 38
    Stanford JL, Thomas DB. Exogenous progestins and breast cancer. Epidemiol Rev 1993; 15: 98107.
  • 39
    Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 32133.
  • 40
    Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004; 291: 170112.
  • 41
    Druckmann R. Progestins and their effects on the breast. Maturitas. 2003; 46 ( Suppl 1): S59S69.
  • 42
    Taneepanichskul S, Intaraprasert S, Theppisai U, Chaturachinda K. Bone mineral density during long-term treatment with Norplant implants and depot medroxyprogesterone acetate. A cross-sectional study of Thai women. Contraception 1997; 56: 1535.
  • 43
    Xu B, Kitawaki J, Koshiba H, Ishihara H, Kiyomizu M, Teramoto M, Kitaoka Y, Honjo H. Differential effects of progestogens, by type and regimen, on estrogen-metabolizing enzymes in human breast cancer cells. Maturitas 2007; 56: 14252.
  • 44
    Sivin I. Risks and benefits, advantages and disadvantages of levonorgestrel-releasing contraceptive implants. Drug Saf 2003; 26: 30335.
  • 45
    Jensen JT. Contraceptive and therapeutic effects of the levonorgestrel intrauterine system: an overview. Obstet Gynecol Surv 2005; 60: 60412.
  • 46
    Backman T, Rauramo I, Jaakkola K, Inki P, Vaahtera K, Launonen A, Koskenvuo M. Use of the levonorgestrel-releasing intrauterine system and breast cancer. Obstet Gynecol 2005; 106: 81317.